# Molecular diagnostic yield of genome sequencing versus targeted gene panel testing in racially and ethnically diverse pediatric patients

**Supplementary Online Content** 

eMethods 1. Mapping population groups

eMethods 2. Targeted gene panel testing

eMethods 3. Genome sequencing

eMethods 4. In silico analysis of diagnostic yield

eReferences

eTable 2. Proband phenotypes and targeted gene panels ordered in the NYCKidSeq study

eTable 3. Clinical interpretation of genetic testing in 645 probands at the time of initial and final

genome sequencing reports

**eTable 4.** Secondary findings reported in 13 of the 503 NYCKidSeq participants who opted to receive secondary findings

eTable 6. Uncertain clinical interpretations across population groups in the NYCKidSeq study

eTable 7. Discrepancies observed between targeted gene panel and genome sequencing

reports among probands with a molecular diagnosis

**eTable 9.** *In silico* analysis of diagnostic yield using a combination of seven commercially available targeted gene panels

**eFigure 1.** Concordance of detected variants between targeted gene panel (TGP) testing and genome sequencing (GS) in 113 probands who received a molecular diagnosis.

#### eMethods 1. Mapping population groups

Parents/legal guardians completed a baseline survey (77% in English and 23% in Spanish) at enrollment, in which they were asked to select the racial and/or ethnic category or categories that best described their child.<sup>1</sup> Categories were: American Indian, Native American, or Alaska Native; Asian; Black or African American; Native Hawaiian/Pacific Islander; White or European American; Middle Eastern or North African/Mediterranean; Hispanic/Latino(a); prefer not to answer; unknown/none of these fully describe my child; and other category. Individuals who selected multiple categories including "Hispanic/Latino(a)" were designated as "Hispanic/Latino(a)". All other individuals who selected multiple categories were designated as "more than one population selected".

#### eMethods 2. Targeted gene panel testing

Clinical targeted gene panel (TGP) testing was performed at Sema4.<sup>2</sup> Genomic DNA was extracted from the probands' blood or saliva specimens using standard methods. The three TGPs used in the study consisted of a neurodevelopmental panel (447 genes), a comprehensive immunodeficiency panel (250 genes), and a comprehensive cardiovascular panel (240 genes) from Sema4 (**eTable 1**). One or more of the panels were ordered based on the participant's phenotype. Agilent SureSelectTM QXT DNA library prep kits with a custom capture library were used, which included the exonic regions of genes on the panel, +/- 5 bps at the exon/intron junctions, and previously reported variants in non-coding regions within the targeted genes. Illumina NovaSeq platform (Xp workflow) with 100-bp paired-end reads was used to sequence proband samples. Reference build GRCh37/hg19 was used for alignment and variant calling. A

minimum coverage of 20X was established and bioinformatic algorithms designed and validated by the laboratory were used to analyze the sequenced data. Genomic DNA was analyzed by nextgeneration sequencing, copy number variant analysis, and fragile X CGG repeat analysis, as appropriate. Confirmatory methods used included multiplex ligation-dependent probe amplification (MLPA), exon array, quantitative PCR, and Sanger sequencing. Variants were classified according to interpretation guidelines from the American College of Medical Genetics and Genomics (ACMG) and the Association for Medical Pathology (AMP).<sup>3</sup>

## eMethods 3. Genome sequencing

Clinical genome sequencing was performed at the New York Genome Center (NYGC).<sup>4</sup> Genomic DNA was extracted from blood or saliva specimens using standard methods, or DNA extracted at Sema4 was shipped to NYGC. Proband-only analysis was performed for samples submitted from January 2019 to February 2020. KAPA Hyper Prep kit (KAPA Biosystems) was used for sequencing on Illumina HiSeq X instrument (Illumina, CA). DNA sequences from the proband samples were aligned to human genome build 37 (GRCh37/hg19) reference sequence. Reportable variants were confirmed and segregation analysis performed using an orthogonal method such as Sanger sequencing or SNP microarray.

During the course of the study, Illumina provided reagents allowing for additional sequencing of parental samples. Therefore, for samples submitted after February 2020, singleton (probandonly), duo, or trio analysis was completed based on availability of parental samples. TruSeq DNA Nano or TruSeq DNA PCR-free library preparation kits were used for sequencing on the Illumina NovaSeq 6000 instrument (Illumina, CA). DNA sequences from the proband and available

3

parental samples were aligned to human genome build 38 (GRCh38/hg38) reference sequence. Duo or trio re-analysis was also performed for 146 unsolved cases that were previously completed as a proband-only analysis. For this, GS was performed on parental samples using Illumina NovaSeq 6000 instrument (Illumina, CA). DNA sequences from the proband and parental samples were aligned to human genome build 38 (GRCh38/hg38) reference sequence and reanalysis completed as a duo or trio sample. Variants aligned to GRCh37/hg19 were lifted to GRCh38/hg38 for consistency in this manuscript.

All genomes were sequenced with 150 base pair paired-end reads to at least 30X +/- 3X mean coverage, and a minimum of 85% of bases are sequenced to at least 20X coverage. Genomes were analyzed and interpreted using a phenotype-directed approach. Variants were classified using variant interpretation guidelines from the ACMG, AMP, and the Clinical Genome Resource (ClinGen).<sup>3,5,6</sup> Reported variants (except large CNVs) were validated using Variant Validator.

A secondary findings analysis was offered to each individual tested as part of the family-based analysis (*e.g.*, proband and biological parents as part of a trio test) in accordance with the ACMG recommendations for the return of secondary findings. For individuals who opted in to receive secondary findings analysis, a targeted search was conducted for pathogenic or likely pathogenic variants in the following genes:

ACTA2, ACTC1, APC, APOB, ATP7B, BMPR1A, BRCA1, BRCA2, CACNA1S, COL3A1, DSC2, DSG2, DSP, FBN1, GLA, KCNH2, KCNQ1, LDLR, LMNA, MEN1, MLH1, MSH2, MSH6, MUTYH, MYBPC3, MYH11, MYH7, MYL2, MYL3, NF2, OTC, PCSK9, PKP2, PMS2, PRKAG2, PTEN, RB1, RET, RYR1, RYR2, SCN5A, SDHAF2, SDHB, SDHC, SDHD, SMAD3, SMAD4, STK11, TGFBR1, TGFBR2, TMEM43, TNNI3, TNNT2, TP53, TPM1, TSC1, TSC2, VHL, WT1

4

## eMethods 4. In silico analysis of diagnostic yield

We performed an *in silico* analysis to estimate the diagnostic yield from commercially available TGPs not used in the NYCKidSeq study. We selected a set of neurodevelopmental, immunodeficiency, and cardiovascular TGPs from AmbryGenetics<sup>7</sup> and Invitae<sup>8</sup> that are routinely used in clinical practice by medical geneticists to evaluate patients with neurologic, immunologic, and cardiac phenotypes in the two academic medical centers participating in NYCKidSeq. The TGPs were: Ambry NeurodevelopmentNext (202 genes), Ambry EpilepsyNext (124 genes), Invitae Primary Immunodeficiency panel (429 genes), Ambry RhythmNext (42 genes), Ambry HCMNext (30 genes), Ambry TAADNext (35 genes), and Invitae Congenital Heart Disease panel (55 genes). Information about the genes included in these TGPs was accessed online from the two laboratory websites in April 2022 (**eTable 2**).

### eReferences

- Odgis JA, Gallagher KM, Suckiel SA, et al. The NYCKidSeq project: study protocol for a randomized controlled trial incorporating genomics into the clinical care of diverse New York City children. *Trials.* 2021;22(1):56.
- 2. Sema4. <u>https://sema4.com/</u>. Accessed January 21, 2022.
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-424.
- 4. New York Genome Center. <u>https://www.nygenome.org/clinical-products/constitutional-</u> whole-genome-sequencing-wgs-for-undiagnosed-disease/. Accessed January 21, 2022.
- 5. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST, Working Group of the American College of Medical Genetics Laboratory Quality Assurance C. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med.* 2011;13(7):680-685.
- 6. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet Med.* 2020;22(2):245-257.
- 7. AmbryGenetics. <u>https://www.ambrygen.com/</u>. Accessed April 1, 2022.
- 8. Invitae. <u>https://www.invitae.com/en</u>. Accessed April 1, 2022.

**eTable 2.** Proband phenotypes, previous genetic testing, targeted gene panels ordered, and genome sequencing performed in the NYCKidSeq study

Phenotype(s), N = 645	Probands, No. (%)
Cardiac	27 (4.2)
Immunologic	27 (4.2)
Neurologic	554 (85.9)
Cardiac and immunologic	2 (0.3)
Cardiac and neurologic	15 (2.3)
Immunologic and neurologic	18 (2.8)
Cardiac, immunologic, and neurologic	2 (0.3)
Previous genetic testing, N = 192	Probands, No. (%)
Including exome sequencing	31 (16.1)
Including targeted gene panel (no exome sequencing)	104 (54.2)
Other (no exome sequencing or targeted gene panel)	56 (29.2)
Unknown	1 (0.5)
Targeted gene panel(s) ordered, N = 644	Probands, No. (%)
Cardiovascular	28 (4.3)
Immunodeficiency	29 (4.5)
Neurodevelopmental	558 (86.6)
Cardiovascular and immunodeficiency	3 (0.5)
Cardiovascular and neurodevelopmental	12 (1.9)
Immunodeficiency and neurodevelopmental	14 (2.2)
Genome sequencing performed, N = 643	Probands, No. (%)
Singleton	26 (4.0)
Duo	220 (34.2)
Trio	397 (61.7)

**eTable 3.** Clinical interpretation of genetic testing and diagnostic yield of targeted gene panel testing and genome sequencing at the time of initial (proband-only) and final genome sequencing reports

Clinical Interpretation	Initial proband-only analysis (N = 343), No. (%)	Final analysis (N = 645), No. (%)	
Positive	44 (12.8)	87 (13.5)	
Likely positive	12 (3.5)	26 (4.0)	
Uncertain	184 (53.6)	373 (57.8)	
Negative	103 30.0)	159 (24.7)	
Positive and likely positive clinical interpretations by test modality	Initial proband-only analysis (N = 343), No. (%)	Final analysis (N = 642), No. (%)	
Targeted gene panel	21 (6.1)	52 (8.1)	
Genome sequencing	53 (15.5)	106 (16.5)	

Age Group	Sex	Population group	Transcript ID	nscript ID Gene (HGNC ID)		Nucleotide change (HGVS.c)	Amino acid change (HGVS.p)	Variant classification	Parental Inheritance
3 to 12 years	Male	White or European American	NM_000038.6	<i>APC</i> (HGNC:583)	g.112839514T>A	c.3920T>A	p.(lle1307Lys)	Pathogenic	Maternal
>12 years	Male	White or European American	NM_000038.6	<i>APC</i> (HGNC:583)	g.112839514T>A	c.3920T>A	p.(Ile1307Lys)	Pathogenic	Maternal
3 to 12 years	Male	Unknown/none of these fully describe my child	NM_000059.4	BRCA2 (HGNC:1101)	g.32337185A>T	c.2830A>T	p.(Lys944Ter)	Pathogenic	Unknown
3 to 12 years	Female	Hispanic/Latino(a)	NM_000059.4	BRCA2 (HGNC:1101)	g.32339497T>G	c.5142T>G	p.(Tyr1714Ter)	Likely pathogenic	Unknown
3 to 12 years	Male	Hispanic/Latino(a)	NM_000527.5	<i>LDLR</i> (HGNC:6547)	g.11107436G>A	c.862G>A	p.(Glu288Lys)	Pathogenic	Maternal
3 to 12 years	Male	Multiple selected	NM_000527.5	LDLR (HGNC:6547)	g.11116874G>A	c.1721G>A	p.(Arg574His)	Likely pathogenic	Maternal
<3 years	Male	Hispanic/Latino(a)	NM_000257.4	<i>MYH7</i> (HGNC:7577)	g.23431584C>T	c.732+1G>A		Pathogenic	Paternal
3 to 12 years	Male	Multiple selected	NM_020975.6	<i>RET</i> (HGNC:9967)	g.43114598G>C	c.1998G>C	p.(Lys666Asn)	Pathogenic	Maternal
3 to 12 years	Male	Hispanic/Latino(a)	NM_003000.3	<i>SDHB</i> (HGNC:10681)	g.17023975G>A	c.640C>T	p.(Gln214Ter)	Likely pathogenic	Maternal
3 to 12 years	Male	Multiple selected	NM_003001.5	<i>SDHC</i> (HGNC:10682)	g.161314406A>G	c.1A>G	p.(Met1?)	Pathogenic	Unknown
<3 years	Female	Hispanic/Latino(a)	NM_000363.5	<i>TNNI3</i> (HGNC:11947)	g.55154172C>T	c.407G>A	p.(Arg136Gln)	Likely pathogenic	Unknown
>12 years	Male	Asian	NM_001276345. 2	<i>TNNT2</i> (HGNC:11949)	g.201364357G>A	c.430C>T	p.(Arg144Trp)	Likely pathogenic	Maternal
3 to 12 years	Male	Hispanic/Latino(a)	NM_001018005. 2	<i>TPM1</i> (HGNC:12010)	g.63062598C>T	c.725C>T	p.(Ala242Val)	Likely pathogenic	Unknown

eTable 4. Secondary findings reported in 13 of the 503 NYCKedSeq participants who opted to receive secondary findings

Population category	No./total No.	% (95% CI)
American Indian, Native American, or Alaska Native	0/1	-
Asian	25/35	71.4 (54.9 - 83.7)
Black or African American	67/105	63.8 (54.3 - 72.4)
Hispanic/Latino(a)	189/328	57.6 (52.2 - 62.9)
Middle Eastern or North African/Mediterranean	3/5	60.0 (23.1 - 88.2)
White or European American	60/126	47.6 (39.1 - 56.3)
More than one population selected	17/27	63.0 (44.2 - 78.5)
Other	3/4	75.0 (30.1 - 95.4)
Prefer not to answer	4/8	50.0 (21.5 - 78.5)
Unknown/none of these fully describe my child	5/6	83.3 (43.6 - 97.0)

eTable 6. Uncertain clinical interpretations across population groups in the NYCKidSeq study

eTable 7. Discrepancies observed between targeted gene panel and genome sequencing reports among probands with a molecular diagnosis

Gene or chromosomal coordinates	Variant type	Mosaic	Genetic test modality	Clinical interpretation	Type of discrepancy
AIRE (HGNC:360), AIRE (HGNC:360)	Intronic (+ SNV)	No	GS alone	Likely positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
CARD14 (HGNC:16446)	SNV	No	TGP alone	Positive	Variant classifications differed between GS and TGP reports.
FOXG1 (HGNC:3811)	Indel	No	TGP alone	Positive	TGP identified a P/LP variant. GS did not.
GABRB2 (HGNC:4082)	SNV	Yes	GS alone	Likely positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
GNAO1 (HGNC:4389)	Intronic	No	GS alone	Positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
HSD17B10 (HGNC:4800)	SNV	No	GS alone	Positive	Variant classifications differed between GS and TGP reports.
HUWE1 (HGNC:30892)	SNV	No	GS alone	Positive	Variant classifications differed between GS and TGP reports.
<i>IKBKG</i> (HGNC:5961)	Intronic	No	GS alone	Likely positive	GS identified a VUS determined to be causal. TGP did not and gene of interest was analyzed.
KCNQ2 (HGNC:6296)	SNV	No	TGP alone	Likely positive	Variant classifications differed between GS and TGP reports.
KCNQ3 (HGNC:6297)	SNV	No	GS alone	Positive	Variant classifications differed between GS and TGP reports.
NEXMIF (HGNC:29433)	SNV	Yes	TGP alone	Likely positive	TGP identified a P/LP variant. GS did not.
SCN1A (HGNC:10585)	SNV	No	TGP alone	Likely positive	Variant classifications differed between GS and TGP reports.
SCN8A (HGNC:10596)	Intronic	No	TGP alone	Likely positive	Variant classifications differed between GS and TGP reports.
SCN8A (HGNC:10596)	SNV	Yes	GS alone	Likely positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
SCN8A (HGNC:10596)	SNV	No	GS alone	Likely positive	Variant classifications differed between GS and TGP reports.
SCN8A (HGNC:10596)	SNV	No	GS alone	Positive	Variant classifications differed between GS and TGP reports.
SETD5 (HGNC:25566)	SNV	No	GS alone	Positive	Variant classifications differed between GS and TGP reports.
SHANK3 (HGNC:14294)	Indel	No	GS alone	Positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
SOX5 (HGNC:11201)	CNV	No	GS alone	Positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
SOX5 (HGNC:11201)	CNV	No	GS alone	Positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
<i>TGFBI</i> (HGNC:11771), <i>SOS1</i> (HGNC:11187)	SNV, intronic	No	GS alone	Likely positive	GS identified a VUS determined to be causal. TGP did not and gene of interest was analyzed.
<i>TSC2</i> (HGNC:12363)	Intronic	Yes	GS alone	Likely positive	GS identified a VUS determined to be causal. TGP did not and gene of interest was analyzed.
Chr7:150947163_150948277del	CNV	No	GS alone	Positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
Chr9:137661384_137714409del + ASXL3	CNV (+ SNV)	No	GS alone	Positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.
					GS identified a CNV. TGP identified gene duplications or deletions and recommended high-
Chr15:22804175_30375696dup	CNV	Yes	GS alone	Positive	resolution array.
					GS identified a CNV. TGP identified gene duplications or deletions and recommended high-
Chr16:(38502679_46385317)_61223349dup	CNV	No	GS alone	Positive	resolution array.
Chr16:(15308141_15397565)_(16367011_16					
403168)dup	CNV	No	TGP alone	Positive	Variant classifications differed between GS and TGP reports.
					GS identified a CNV. TGP identified gene duplications or deletions and recommended high-
Chr18:1_15400036del	CNV	No	GS alone	Positive	resolution array.
					GS identified a CNV. TGP identified gene duplications or deletions and recommended high-
Chr20:63255263_63498365del	CNV	No	GS alone	Positive	resolution array.
ChrX:18592341_18596203del	CNV	Yes	GS alone	Likely positive	GS identified a P/LP variant. TGP did not and gene of interest was analyzed.

CNV, copy number variant; GS, genome sequencing; Indel, insertion/deletion; P/LP, pathogenic/likely pathogenic; SNV, single nucleotide variant; TGP, targeted gene panel

**eTable 9.** *In silico* analysis of diagnostic yield using a combination of seven commercially available targeted gene panels

Genetic test modality	NYCKidSeq study, N (%)	In silico analysis, N (%)
TGP alone	7 (1.1)	5 (0.8)*
GS alone	61 (9.5)	41 (6.4)
TGP and GS	45 (7.0)	65 (10.1)
Diagnostic yield by genetic test modality		
TGP yield	52 (8.1)	70 (10.9)
GS yield	106 (16.5)	106 (16.5)
Total yield	113 (17.6)	111 (17.3)

\* The two TGP-only variants not detected by this combination of commercially available targeted gene panels were *NEXMIF* c.2030C>A (mosaic) and Chr16:(15308141\_15397565)\_(16367011\_16403168)dup (CNV)

Variant type	TGP alone	TGP and GS	GS alone		
CNV	0	2	12 (2)	_ Variant 1	Variant 2
Indel	1	15	9	SNV	CNV
Intronic	0	10	4 (1)	SNV SNV	CNV CNV
SNV	1 (1)	29 (1)	23 (3)	SNV	CNV
Multiple types	0	0	7 ——	SNV SNV	Intronic Intronic
	2	56	55	Indel	CNV

**eFigure 1.** Concordance of detected variants between targeted gene panel (TGP) testing and genome sequencing (GS) in 113 probands who received a molecular diagnosis. The number and types of variants detected by TGP testing, GS, or both test modalities are shown. In contrast with **Figure 2**, here we considered 11 cases with variant classification differences (see **eTable 7**) as being identified by both test modalities. Eight mosaic variants were identified, including six by GS alone, one by TGP testing alone, and one by both modalities; these are indicated in parentheses for each test modality and variant type. There were seven probands for whom two distinct variants were identified (*i.e.*, multiple types). CNV, copy number variant; Indel, insertion/deletion; SNV; single nucleotide variant.